High-density lipoprotein cholesterol raising: Does it matter?

Current Opinion in Cardiology

Volumn 28, Issue 4, 2013, Pages 464-474

  Schofield, Jonathan D ^a,b   France, Michael ^a,b   Ammori, Basil ^b,c   Liu, Yifen ^b   Soran, Handrean ^a,b  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

cardiovascular disease; HDL functionality; HDL cholesterol

Indexed keywords

ANACETRAPIB; APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE 1; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; DALCETRAPIB; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; ROSUVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HUMAN; HYPERTRIGLYCERIDEMIA; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; PREDICTOR VARIABLE; PRIORITY JOURNAL; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; HUMANS; NIACIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK REDUCTION BEHAVIOR; SULFHYDRYL COMPOUNDS;

EID: 84879993222     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e328362210d     Document Type: Review

References (117)

1. Bhatt KN, Wells BJ, Sperling LS, Baer JT. High-density lipoprotein therapy: is there hope? Curr Treat Options Cardiovasc Med 2010; 12:315-328.
2. Seo SM, Choo EH, Koh YS, et al. High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention. Heart 2011; 97:1943-1950.
3. Bhatnagar D, Soran H, Durrington PN. Hypercholesterolaemia and its management. BMJ 2008; 337:a993.
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Studyofcholesterol loweringwith simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
5. Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and other societies on cardio-vasculardisease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Atherosclerosis 2012; 223:1-68.
6. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefitwith niacin. JAm Coll Cardiol 1986; 8:1245-1255.
7. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and cor-onary venous bypass grafts. JAMA 1987; 257:3233-3240.
8. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and de-velopment of ischaemic heart-disease. Lancet 1975; 1:16-19.
9. Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986; 256:2835-2838.
10. Mahdy Ali K, Wonnerth A, Huber K, Wojta J. Cardiovascular disease risk reduction by raising HDL cholesterol-current therapies and future oppor-tunities. Br J Pharmacol 2012; 167:1177-1194.
11. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protectivefactoragainstcoronary heartdisease. The Framingham Study. Am J Med 1977; 62:707-714.
12. Olsson AG, Schwartz GG, Szarek M, et al. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J 2005; 26:890-896.
13. Mureddu GF, Brandimarte F, De Luca L. High-density lipoprotein levels and risk of cardiovascular events: a review. J Cardiovasc Med (Hagerstown) 2012; 13:575-586.
14. Cooney MT, Dudina A, De Bacquer D, et al. Howmuch does HDLcholesterol add to risk estimation? A report from the SCORE Investigators. Eur J Cardiovasc Prev Rehabil 2009; 16:304-314.
15. Siri-Tarino PW. Effects of diet on high-density lipoprotein cholesterol. Curr Atheroscler Rep 2011; 13:453-460.
16. Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospectivestudieswith 55, 000vasculardeaths. Lancet 2007; 370:1829-1839.
17. Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302:1993-2000.
18. Barter P, Gotto AM, La Rosa JC, et al. HDLcholesterol, very lowlevelsofLDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357:1301-1310.
19. Castelli WP.Cholesterol and lipids intheriskofcoronaryarterydisease-the Framingham Heart Study. Can J Cardiol 1988; 4 (Suppl. A):5A-10A.
20. Dhingra R, Sesso HD, Kenchaiah S, Gaziano JM. Differential effects of lipids on the risk of heart failure and coronary heart disease: the Physicians' Health Study. Am Heart J 2008; 155:869-875.
21. Fruchart JC, Sacks F, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008; 102 (10 Suppl.):1K-34K.
22. Asplund K, Karvanen J, Giampaoli S, et al. Relative risksforstroke byage, sex, and population based on follow-up of 18 European populations in the MORGAM Project. Stroke 2009; 40:2319-2326.
23. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.
24. Jafri H, Alsheikh-Ali AA, Karas RH. Meta-analysis:statintherapydoes notalter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med 2010; 153:800-808.
25. Mora S, Wenger NK, Demicco DA, et al. Determinants of residual risk in secondarypreventionpatientstreatedwithhigh-versuslow-dosestatintherapy: theTreatingto New Targets (TNT)study.Circulation 2012; 125:1979-1987.
26. Alsheikh-Ali AA, Lin JL, Abourjaily P, et al. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. Am J Cardiol 2007; 100:1499-1501.
27. Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high riskofcardiovas-cular disease: evidence and guidance for management. Eur Heart J 2011; 32:1345-1361.
28. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005; 45:185-197.
29. ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362:1563-1574.
30. Tonkin AM, Chen L. Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovas-cular Risk in Diabetes (ACCORD) trial. Circulation 2010; 122:850-852.
31. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001; 285:1585-1591.
32. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009; 361:2113-2122.
33. Villines TC, Stanek EJ, Devine PJ, et al. The ARBITER 6-HALTSTrial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Choles-terol 6-HDL and LDLTreatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol 2010; 55:2721-2726.
34. Krauss RM, Williams PT. Alcohol and the heart: does raising high-density lipoprotein matter? Circulation 2011; 124:2283-2284.
35. Durrington PN. Hyperlipidaemia: diagnosis and management. 3rd ed. London: Hodder Arnold; 2007:; xv, p. 399, p. 12 of plates.
36. Soran H, Hama S, Yadav R, Durrington PN. HDL functionality. Curr Opin Lipidol 2012; 23:353-366.
37. Fisher EA, Feig JE, Hewing B, et al. High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2012; 32:2813-2820.
38. Rosenson RS, Brewer HB Jr, Chapman MJ, et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic car-diovascular events. Clin Chem 2011; 57:392-410.
39. Salonen JT, Salonen R, Seppanen K, et al. HDL, HDL2, and HDL3 subfrac-tions, and the risk of acute myocardial infarction. A prospective population study in Eastern Finnish men. Circulation 1991; 84:129-139.
40. Kontush A, Chapman MJ. Antiatherogenic function of HDL particle subpo-pulations:focus on antioxidative activities. Curr Opin Lipidol 2010; 21:312-318.
41. Rye KA, Bursill CA, Lambert G, et al. The metabolism and antiatherogenic properties of HDL. J Lipid Res 2009; 50 (Suppl.):S195-S200.
42. Eren E, Yilmaz N, Aydin O. High density lipoprotein and its dysfunction. Open Biochem J 2012; 6:78-93.
43. Movva R, Rader DJ. Laboratory assessment of HDL heterogeneity and function. Clin Chem 2008; 54:788-800.
44. Soran H, Younis NN, Charlton-Menys V, Durrington P. Variation in paraox-onase-1 activity and atherosclerosis. Curr Opin Lipidol 2009; 20:265-274.
45. Asztalos BF, Tani M, Schaefer EJ. Metabolic and functional relevance of HDL subspecies. Curr Opin Lipidol 2011; 22:176-185.
46. Rader DJ, Alexander ET, Weibel GL, et al. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res 2009; 50 (Suppl.):S189-S194.
47. Yin K, Liao DF, Tang CK. ATP-binding membrane cassette transporter A1 (ABCA1): a possible link between inflammation and reverse cholesterol transport. Mol Med 2010; 16:438-449.
48. Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 1973; 180:1332-1339.
49. Barter P. HDL-C: role as a risk modifier. Atheroscler Suppl 2011; 12:267-270.
50. Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol. Mod-ifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320:915-924.
51. Younis N, Charlton-Menys V, Sharma R, et al. Glycation of LDLin nondiabetic people: Small dense LDL is preferentially glycated both in vivo and in vitro. Atherosclerosis 2009; 202:162-168.
52. Baker PW, Rye KA, Gamble JR, et al. Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. J Lipid Res 1999; 40:345-353.
53. Wang SH, Yuan SG, Peng DQ, Zhao SP. High-density lipoprotein affects antigen presentation by interfering with lipid raft: a promising antiatherogenic strategy. Clin Exp Immunol 2010; 160:137-142.
54. Mousa SS, Block RC, Mousa SA. High density lipoprotein (HDL) modulation targets. Drugs Future 2010; 35:33-39.
55. Angeli V, Llodra J, Rong JX, et al. Dyslipidemiaassociated with atherosclero-tic disease systemically alters dendritic cell mobilization. Immunity 2004; 21:561-574.
56. Karliner JS. Sphingosine kinase and sphingosine 1-phosphate in cardiopro-tection. J Cardiovasc Pharmacol 2009; 53:189-197.
57. Zhang Q, Liu L, Zheng XY. Protective roles of HDL, apoA-I and mimetic peptide on endothelial function: through endothelial cells and endothelial progenitorcells. Int J Cardiol 2009; 133:286-292.
58. Oslakovic C, Krisinger MJ, Andersson A, et al. Anionic phospholipids lose their procoagulant properties when incorporated into high density lipopro-teins. J Biol Chem 2009; 284:5896-5904.
59. Younis NN, Soran H, Charlton-Menys V, et al. High-density lipoprotein impedes glycation of low-density lipoprotein. Diab Vasc Dis Res 2013; 10:152-160.
60. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and riskof myocardial infarction: a Mendelian randomisation study. Lancet 2012; 380:572-580.
61. Smith JD. Dysfunctional HDL as a diagnostic and therapeutic target. Arter-ioscler Thromb Vasc Biol 2010; 30:151-155.
62. Navab M, Reddy ST, Van Lenten BJ, et al. The role of dysfunctional HDL in atherosclerosis. J Lipid Res 2009; 50 (Suppl.):S145-S149.
63. Yilmaz N. Relationship between paraoxonase and homocysteine: crossroads of oxidative diseases. Arch Med Sci 2012; 8:138-153.
64. Kalantar-Zadeh K, Kopple JD, Kamranpour N, et al. HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int 2007; 72:1149-1156.
65. Navab M, Hama SY, Anantharamaiah GM, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 2000; 41:1495-1508.
66. Navab M, Hama SY, Hough GP, et al. Acell-freeassayfordetecting HDLthat is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 2001; 42:1308-1317.
67. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364:127-135.
68. Fitzgerald ML, Mujawar Z, Tamehiro N. ABC transporters, atherosclerosis and inflammation. Atherosclerosis 2010; 211:361-370.
69. Sato K, Okajima F. Role of sphingosine 1-phosphate in antiatherogenic actions of high-density lipoprotein. World J Biol Chem 2010; 1:327-337.
70. Alexander ET, Tanaka M, Kono M, et al. Structural and functional conse-quences of the Milano mutation (R173C) in human apolipoprotein A-I. J Lipid Res 2009; 50:1409-1419.
71. Calabresi L, Simonelli S, Gomaraschi M, Franceschini G. Genetic lecithin:ch-olesterol acyltransferase deficiency and cardiovascular disease. Athero-sclerosis 2012; 222:299-306.
72. Barter PJ, Kastelein JJ. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J Am Coll Cardiol 2006; 47:492-499.
73. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227-239.
74. Hausenloy DJ, Yellon DM. Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels. Curr Opin Cardiol 2009; 24:473-482.
75. Bos MB, deVries JH, Feskens EJ, et al. Effectofahigh monounsaturatedfatty acids diet and a Mediterranean diet on serum lipids and insulin sensitivity in adults with mild abdominal obesity. Nutr Metab Cardiovasc Dis 2010; 20:591-598.
76. Nimptsch K, Brand-Miller JC, Franz M, et al. Dietary insulin indexand insulin load in relation to biomarkers of glycemic control, plasma lipids, and inflam-mation markers. Am J Clin Nutr 2011; 94:182-190.
77. Roberts CK, Ng C, Hama S, et al. Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in over-weight/obese men with cardiovascular risk factors. J Appl Physiol 2006; 101:1727-1732.
78. Mooradian AD, Haas MJ, Wehmeier KR, Wong NC. Obesity-related changes in high-density lipoprotein metabolism. Obesity (Silver Spring) 2008; 16:1152-1160.
79. Ansell BJ, Fonarow GC, Fogelman AM. High-density lipoprotein: is it always atheroprotective? Curr Atheroscler Rep 2006; 8:405-411.
80. Magnus P, Bakke E, Hoff DA, et al. Controlling for high-density lipoprotein cholesterol does notaffectthemagnitudeof the relationshipbetween alcohol and coronary heart disease. Circulation 2011; 124:2296-2302.
81. Beulens JW, Sierksma A, van Tol A, et al. Moderate alcohol consumption increases cholesterol efflux mediated by ABCA1. J Lipid Res 2004; 45:1716-1723.
82. Cholesterol Treatment Triallists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet 2010; 376:1670-1681.
83. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295:1556-1565.
84. Ballantyne CM, Herd JS, Ferlic LL, et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 1999; 99:736-743.
85. Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipi-daemia and future perspectives. Atherosclerosis 2003; 171:1-13.
86. Andreou I, Tousoulis D, Miliou A, et al. Effects of rosuvastatin on myeloper-oxidase levels in patients with chronic heart failure: a randomized placebo-controlled study. Atherosclerosis 2010; 210:194-198.
87. Harangi M, Mirdamadi HZ, Seres I, et al. Atorvastatin effecton thedistribution of high-density lipoprotein subfractions and human paraoxonase activity. Transl Res 2009; 153:190-198.
88. Goldenberg I, Benderly M, Goldbourt U. Secondary prevention with bezafi-brate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial. J Am Coll Cardiol 2008; 51:459-465.
89. Saha SA, Kizhakepunnur LG, Bahekar A, Arora RR. The role offibrates in the prevention of cardiovascular disease-a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J 2007; 154:943-953.
90. Goldenberg I, Benderly M, Sidi R, et al. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial). Am J Cardiol 2009; 103:41-45.
91. Wierzbicki AS, Hardman TC, Viljoen A. New lipid-lowering drugs: an update. Int J Clin Pract 2012; 66:270-280.
92. Zhao XQ, Krasuski RA, Baer J, et al. Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascularevents in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS). Am J Cardiol 2009; 104:1457-1464.
93. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345:1583-1592.
94. Guyton JR. Effect of niacin on atherosclerotic cardiovascular disease. Am J Cardiol 1998; 82:18U-23U; discussion 39U-41U.
95. Brown G, Albers JJ, Fisher LD, et al. Regression ofcoronaryarterydisease as a result of intensive lipid-lowering therapy in men with high levels of apoli-poprotein B. N Engl J Med 1990; 323:1289-1298.
96. Taylor AJ, Kent SM, Flaherty PJ, et al. ARBITER: Arterial Biology for the Investigation oftheTreatment Effectsof Reducing Cholesterol: arandomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002; 106:2055-2060.
97. Brinton EA. Search and rescue for hypotheses surviving AIM-HIGH, the niacin therapy earthquake: still problematic after the primary publication. J Clin Lipidol 2012; 6:312-317.
98. University of Oxford Clinical Trial Service Unit and Epidemiological Studies Unit HPS2-THRIVE website: www.thrivestudy.org. [Accessed 28 March 2013]
99. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, prespecified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013; 34:1279-1291.
100. Barter PJ, Caulfield M, Eriksson M, et al. Effects oftorcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357:2109-2122.
101. Barter P. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Am J Cardiol 2009; 104 (10 Suppl.):10E-15E.
102. Yvan-Charvet L, Matsuura F, Wang N, et al. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol 2007; 27:1132-1138.
103. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367:2089-2099.
104. Cannon CP, Shah S, Dansky HM, et al. Safetyofanacetrapib in patientswith or at high riskfor coronary heart disease. N Engl J Med 2010; 363:2406-2415.
105. Fayad ZA, Mani V, Woodward M, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel noninvasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 2011; 378:1547-1559.
106. Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011; 306:2099-2109.
107. Nicholls SJ, Dusting GJ, Cutri B, et al. Reconstituted high-density lipopro-teins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 2005; 111:1543-1550.
108. Bailey D, Ruel I, Hafiane A, et al. Analysis of lipid transfer activity between model nascent HDL particles and plasma lipoproteins: implications for current concepts of nascent HDL maturation and genesis. J Lipid Res 2010; 51:785-797.
109. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007; 356:1304-1316.
110. Bloedon LT, Dunbar R, Duffy D, et al. Safety, pharmacokinetics, and phar-macodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovas-cular patients. J Lipid Res 2008; 49:1344-1352.
111. Bailey D, Jahagirdar R, Gordon A, et al. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol 2010; 55:2580-2589.
112. Tardif JC, Gregoire J, L-Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007; 297:1675-1682.
113. Pfeifer T, Buchebner M, Chandak PG, et al. Synthetic LXR agonist sup-presses endogenous cholesterol biosynthesis and efficiently lowers plasma cholesterol. Curr Pharm Biotechnol 2011; 12:285-292.
114. Briel M, Ferreira-Gonzalez I, You JJ, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mor-tality: systematic review and meta-regression analysis. BMJ 2009; 338:b92.
115. Singh V, Sharma R, Kumar A. Low high-density lipoprotein cholesterol: current status and future strategies for management. Vasc Health Risk Manag 2010; 6:979-996.
116. Valiyaveettil M, Kar N, Ashraf MZ, et al. Oxidized high-density lipoprotein inhibits platelet activation and aggregation via scavenger receptor BI. Blood 2008; 111:1962-1971.
117. Page ST, Krauss RM, Gross C, et al. Impactofmifepristone, aglucocorticoid/progesterone antagonist, on HDL cholesterol, HDL particle concentration, and HDLfunction. J Clin Endocrinol Metab 2012; 97:1598-1605.